Sugammadex + Neostigmine/Glycopyrrolate
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Complications
Conditions
Pulmonary Complications
Trial Timeline
Dec 3, 2018 → Jan 1, 2021
NCT ID
NCT02825576About Sugammadex + Neostigmine/Glycopyrrolate
Sugammadex + Neostigmine/Glycopyrrolate is a approved stage product being developed by Merck for Pulmonary Complications. The current trial status is terminated. This product is registered under clinical trial identifier NCT02825576. Target conditions include Pulmonary Complications.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Complications were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02825576 | Approved | Terminated |
Competing Products
20 competing products in Pulmonary Complications